MedPath

Methadone-Maintained Smokers Switching to E-Cigarettes

Phase 4
Active, not recruiting
Conditions
Nicotine Dependence
Electronic Cigarette Use
Interventions
Drug: Electronic Cigarette
Registration Number
NCT05206435
Lead Sponsor
Butler Hospital
Brief Summary

Participants in this randomized clinical trial will be methadone-maintained smokers interested in switching to electronic cigarettes (ECs). There will be a total of 7 study visits over the course of 6 weeks; each visit includes psychometric assessment and biomarker measurements. After completion of the baseline visit, participants will be randomized to either: 1) 6 weeks of EC use (JUUL 5% nicotine pods) or 2) 6 weeks of nicotine replacement therapy (NRT) in the form of nicotine lozenges. EC and NRT use will begin the day after the baseline assessment.

Detailed Description

Participants in this randomized clinical trial will be methadone-maintained smokers interested in switching to electronic cigarettes (ECs). There will be a total of 7 study visits over the course of 6 weeks: baseline, 5 weekly check-in (CI) visits, and a 6-week assessment. Baseline assessments will include biomarker measurement, carbon monoxide (CO) readings, smoking history and current cigarette use, spirometry, respiratory symptoms, and tobacco demand. After completion of the baseline visit, participants will be randomized to either: 1) 6 weeks of EC use (JUUL 5% nicotine pods) or 2) 6 weeks of nicotine replacement therapy (NRT) in the form of nicotine lozenges. EC and NRT use will begin the day after the baseline assessment.

All participants will attend weekly brief assessment check-in visits where distribution of either EC or NRT will occur. Check-in assessments will include cigarette use, EC use, NRT use, CO readings, respiratory symptoms, and tobacco demand. At the 6-week assessment, baseline measurements will be repeated to determine changes in the health effects, biomarkers, and combustible cigarette use associated with 6 weeks of EC use, relative to NRT.

This study will be the first to test the potential behavioral and health effects of ECs in smokers with opioid use disorder, a population that is highly dependent on nicotine, highly vulnerable to smoking-related morbidity and mortality, and searching for novel methods to lower smoking-related risks.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
240
Inclusion Criteria
  • moderate to heavy cigarette smokers (10 cigarettes/day for > 1 yr; breath CO > 10 ppm)
  • have been receiving methadone for at least three months
  • attend at least weekly to receive methadone dose
  • speak English
  • have a telephone or access to a telephone
  • are available over the next 6 weeks
  • are interested in switching to either electronic cigarettes or nicotine replacement therapy
Exclusion Criteria
  • use of ECs on > 2 of the past 30 days
  • currently use medications that may reduce smoking (e.g., bupropion, varenicline, NRT)
  • have unstable psychiatric conditions
  • have near-daily or daily use of marijuana
  • are pregnant
  • had a cardiovascular event in the last month
  • daily medication for asthma or COPD

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nicotine LozengesNicotine LozengeParticipants in this arm are randomized to receive nicotine lozenge for the 6-week study period.
Electronic CigarettesElectronic CigaretteParticipants in this arm are randomized to receive electronic cigarettes for the 6-week study period.
Primary Outcome Measures
NameTimeMethod
FVC Lung Functioning6 weeks

Changes in Forced Vital Capacity (FVC), as measured by spirometry at baseline and again at 6-weeks.

FEV1 Lung Functioning6 weeks

Changes in Forced Expiratory Volume (FEV - during the first second), as measured by spirometry at baseline and again at 6-weeks.

FEV1 Lung Functioning for Complete Switchers6 weeks

Changes in Forced Expiratory Volume (FEV - during the first second), as measured by spirometry at baseline and again at 6-weeks, among complete switchers, irrespective of condition, (i.e., exclusive EC/NRT users based on 7-day carbon monoxide (CO)-verified reports at the 6-week time point) relative to dual users and exclusive CC users.

Nicotine Exposure for Complete Switchers6 weeks

Extent of Nicotine Exposure as measured by urine-based tobacco toxicology assessment at baseline and again at 6-week among complete switchers, irrespective of condition, (i.e., exclusive EC/NRT users based on 7-day carbon monoxide (CO)-verified reports at the 6-week time point) relative to dual users and exclusive CC users.

Smoking Behavior and Experiences for Complete Switchers6 weeks

Changes in smoking behavior and experiences, as measured by self-report at baseline and again at 6-weeks, among complete switchers, irrespective of condition, (i.e., exclusive EC/NRT users based on 7-day carbon monoxide (CO)-verified reports at the 6-week time point) relative to dual users and exclusive CC users.

FEV1/FVC Ratio Lung Functioning for Complete Switchers6 weeks

Changes in FEV1/FVC ratio, as measured by spirometry at baseline and again at 6-weeks, among complete switchers, irrespective of condition, (i.e., exclusive EC/NRT users based on 7-day carbon monoxide (CO)-verified reports at the 6-week time point) relative to dual users and exclusive CC users.

Nicotine Exposure6 weeks

Extent of Nicotine Exposure as measured by urine-based tobacco toxicology assessment at baseline and again at 6-weeks.

FEV1/FVC Ratio Lung Functioning6 weeks

Changes in FEV1/FVC ratio, as measured by spirometry at baseline and again at 6-weeks.

Smoking Behavior and Experiences6 weeks

Changes in smoking behavior and experiences, as measured by self-report at baseline and again at 6-weeks.

FVC Lung Functioning for Complete Switchers6 weeks

Changes in Forced Vital Capacity (FVC), as measured by spirometry at baseline and again at 6-weeks, among complete switchers, irrespective of condition, (i.e., exclusive EC/NRT users based on 7-day carbon monoxide (CO)-verified reports at the 6-week time point) relative to dual users and exclusive CC users.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Butler Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath